Friedrich Graf Finckenstein

Company: Iovance Biotherapeutics

Job title: CMO

Seminars:

Clinical Success of the Iovance TIL Technology Platform in Solid Tumors 10:30 am

• Highlight advantages of polyclonal TIL MOA for solid tumors • Review positive clinical data for TIL in metastatic melanoma and other solid tumor types • Explore next-generation approaches: combinations and genetically modified TILRead more

day: Day Two